CRNX

News Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential

14d ago

News Crinetics Pharmaceuticals exec sells shares worth over $645,000 - Investing.com

14d ago

News Crinetics outlines plan to exceed 75% Palsonify coverage by end of Q3 2026 while funding operations into 2030

20d ago

Insider trade Sale by Jeff E. Knight (Chief Dev. & Operating Officer)

52d ago

SEC filing CRNX Announces Jeff Knight Resignation, $400/hr Consulting Deal, Forfeited RSUs, Extended Indemnity

52d ago

News Indivior, Liquidia, Crinetics top Quant pharma list as Merck scoops up Terns for $6.7B

69d ago

SEC filing CRNX Announces CEO Jeff Knight Resignation Effective April 10, 2026, Succession Plan in Place

71d ago

Insider trade Sale by Stephen F. Betz (Chief Scientific Officer)

75d ago

Insider trade Sale by Struthers Richard Scott (President & CEO)

75d ago

Insider trade Sale by Jeff E. Knight (Chief Operating Officer)

75d ago

Insider trade Sale by Coelho Rogerio Vivaldi

80d ago

Insider trade Sale by Stephanie Okey

89d ago

Insider trade Sale by Tobin Schilke (Chief Financial Officer)

89d ago

News Crinetics outlines $600M–$650M 2026 operating expense plan as PALSONIFY launch accelerates

95d ago

News Goldman Sachs Upgrades Crinetics Pharmaceuticals, Inc. (CRNX) To Buy From Neutral

138d ago

News Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock

146d ago

News Mezzion Pharmaceuticals Appoints Physician-Scientist Ridwan Shabsigh, MD, FACS as President & Chief Operating Officer

147d ago

News Crinetics plans $350 mln public share offering

147d ago

News Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock

147d ago

News Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia

148d ago

News Why Crinetics Pharmaceuticals Stock Was Sliding on Friday

153d ago